Immunalysis competitors

Barry Quart, Pharm.D. has served as a director of Heron since 2012. Dr. Quart was appointed Chief Executive Officer of the Company in 2013 and President and Chief Executive Officer of the Company in February 2019. Dr. Quart has more than 25 years of experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc. and served as its President and Chief Executive Officer from its inception through 2013 and as a director through its acquisition by AstraZeneca PLC in 2012. Previously, he was with Pfizer Inc. as Senior Vice President of Pfizer Global Research and Development, and the director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of Viracept® (nelfinavir). Dr. Quart also served as a director of Synageva Biopharma Corp. from 2012 through its acquisition by Alexion Pharmaceuticals, Inc. in 2015. Since 2015, Dr. Quart has served as a director of Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company. Dr. Quart received a Pharm.D. degree from the University of California, San Francisco.

John Adent is a Board Member at NEOGEN CORP and President/CEO at NEOGEN CORP and is based in Lansing, Michigan. He has worked as Chief Executive Officer at ANIMAL HEALTH HOLDINGS, INC. and Pres & CEO:Animal Health at PATTERSON COMPANIES, INC.. John studied at DEPAUW UNIVERSITY between 1986 and 1990.

An accomplished Board Chairman, Chief Executive Officer, and civic leader, with a career built on professional will and personal humility. Strengths: Moral Fortitude, General Management, Entrepreneurship, Business Strategy, Applied Technology, Deal Making. (Note: Please do not use LinkedIn email to request meetings or responses. I rarely check LinkedIn email and even less frequently respond. I ask respectfully, so we both use our time and efforts productively. Thank you.)

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.